3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
47
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Neoplasm, Residual
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Interventions
durvalumab
9
Bevacizumab
8
tremelimumab
4
lenvatinib
3
atezolizumab
3
Nivolumab
3
Ipilimumab
3
fludarabine
2
Magnetic Resonance Imaging
2
Hepatectomy
2
Gemcitabine
2
Cyclophosphamide
2
Cisplatin
2
trastuzumab deruxtecan
1
toripalimab
1
ropidoxuridine
1
poly ICLC
1
pembrolizumab
1
brodalumab
1
X-Rays
1
Whole Genome Sequencing
1
Technetium Tc 99m Aggregated Albumin
1
Standard of Care
1
Specimen Handling
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy
1
Radiosurgery
1
Radionuclide Imaging
1
Pregabalin
1
Pluvicto
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
enzalutamide
×
90 days
×
Clear all
No trials found.